These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 37394761)
1. Severe soft tissue infection: A complication of mpox in an individual with HIV coinfection requiring vaccinia intravenous immunoglobulin and intravenous tecovirimat. Mahtani AU; Seelam H; Padda I; Mahmoud M; D Cuomo J; Khalil BW; Haider M; Khalil A; Elemam A; Nfonoyim J J Med Virol; 2023 Jul; 95(7):e28917. PubMed ID: 37394761 [TBL] [Abstract][Full Text] [Related]
2. The use of Vaccinia Immune Globulin in the Treatment of Severe Mpox. Virus Infection in Human Immunodeficiency Virus/AIDS. Thet AK; Kelly PJ; Kasule SN; Shah AK; Chawala A; Latif A; Chilimuri SS; Zeana CB Clin Infect Dis; 2023 May; 76(9):1671-1673. PubMed ID: 36571287 [TBL] [Abstract][Full Text] [Related]
3. Intravenous tecovirimat treatment of oral monkeypox lesions in a patient with HIV-1. Chen WH; Axell-House DB J Med Virol; 2023 Sep; 95(9):e29078. PubMed ID: 37665172 [TBL] [Abstract][Full Text] [Related]
4. Treatment options for severe or refractory mpox virus infection in patients with advanced HIV. Pettit NN; Imam S; Sherer R; Hazra A Int J STD AIDS; 2023 May; 34(6):366-373. PubMed ID: 36708269 [TBL] [Abstract][Full Text] [Related]
5. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report. Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf. De Clercq E; Jiang Y; Li G Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022. Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215 [TBL] [Abstract][Full Text] [Related]
8. A 40-Year-Old Man with Anemia, Proctitis, Rectal Bleeding, and a Perianal Rash Due to Mpox (Monkeypox) Infection. Moore C; Marcucci V; Torres P; Liu E; Parker GS Am J Case Rep; 2023 Sep; 24():e940177. PubMed ID: 37660250 [TBL] [Abstract][Full Text] [Related]
9. Tecovirimat for the treatment of severe Mpox in Germany. Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167 [TBL] [Abstract][Full Text] [Related]
10. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study. McLean J; Stoeckle K; Huang S; Berardi J; Gray B; Glesby MJ; Zucker J Ann Intern Med; 2023 May; 176(5):642-648. PubMed ID: 37126820 [TBL] [Abstract][Full Text] [Related]
12. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential. Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis. Shamim MA; Satapathy P; Padhi BK; Veeramachaneni SD; Akhtar N; Pradhan A; Agrawal A; Dwivedi P; Mohanty A; Pradhan KB; Kabir R; Rabaan AA; Alotaibi J; Al Ismail ZA; Alsoliabi ZA; Al Fraij A; Sah R; Rodriguez-Morales AJ Front Pharmacol; 2023; 14():1149909. PubMed ID: 37214444 [TBL] [Abstract][Full Text] [Related]
16. A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome. Viguier C; de Kermel T; Boumaza X; Benmedjahed NS; Izopet J; Pasquier C; Delobel P; Mansuy JM; Martin-Blondel G Int J Infect Dis; 2022 Dec; 125():135-137. PubMed ID: 36397606 [TBL] [Abstract][Full Text] [Related]
17. Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection. Stafford A; Rimmer S; Gilchrist M; Sun K; Davies EP; Waddington CS; Chiu C; Armstrong-James D; Swaine T; Davies F; Gómez CHM; Kumar V; ElHaddad A; Awad Z; Smart C; Mora-Peris B; Muir D; Randell P; Peters J; Chand M; Warrell CE; Rampling T; Cooke G; Dhanji S; Campbell V; Davies C; Osman S; Abbara A Lancet Infect Dis; 2023 Jun; 23(6):e218-e226. PubMed ID: 36773621 [TBL] [Abstract][Full Text] [Related]
18. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023. Rao AK; Schrodt CA; Minhaj FS; Waltenburg MA; Cash-Goldwasser S; Yu Y; Petersen BW; Hutson C; Damon IK MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(9):232-243. PubMed ID: 36862595 [TBL] [Abstract][Full Text] [Related]
19. Progression of human monkeypox infection despite tecovirimat in an immunocompromised adult. Dammann F; Raja M; Camargo JF Transpl Infect Dis; 2023 Feb; 25(1):e14022. PubMed ID: 36714983 [TBL] [Abstract][Full Text] [Related]